GW Pharmaceuticals PLC- (NASDAQ:GWPH) Downgraded to Hold at Zacks Investment Research

Zacks Investment Research downgraded shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) from a buy rating to a hold rating in a report released on Friday, Zacks.com reports.

According to Zacks, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom. “

A number of other research firms also recently weighed in on GWPH. Morgan Stanley increased their target price on shares of GW Pharmaceuticals PLC- to $238.00 and gave the company an overweight rating in a research report on Wednesday, August 7th. ValuEngine raised shares of GW Pharmaceuticals PLC- from a sell rating to a hold rating in a research report on Wednesday, September 4th. Cowen reissued a buy rating and set a $200.00 target price on shares of GW Pharmaceuticals PLC- in a research report on Friday, July 26th. BidaskClub downgraded shares of GW Pharmaceuticals PLC- from a hold rating to a sell rating in a research report on Saturday, November 9th. Finally, Oppenheimer decreased their target price on shares of GW Pharmaceuticals PLC- to $222.00 and set an outperform rating for the company in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have given a buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $199.18.

Shares of GWPH stock traded up $2.40 on Friday, reaching $108.41. The company had a trading volume of 728,900 shares, compared to its average volume of 769,644. The stock has a market capitalization of $3.43 billion, a PE ratio of -10.27 and a beta of 2.28. The business’s 50-day moving average is $120.75 and its 200 day moving average is $152.63. The company has a quick ratio of 6.60, a current ratio of 7.33 and a debt-to-equity ratio of 0.03. GW Pharmaceuticals PLC- has a one year low of $90.14 and a one year high of $196.00.

In other news, insider Douglas B. Snyder sold 5,424 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $13.04, for a total transaction of $70,728.96. Following the completion of the sale, the insider now owns 73,740 shares of the company’s stock, valued at approximately $961,569.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Chairman Geoffrey W. Dr Guy sold 420,000 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $108.41, for a total transaction of $45,532,200.00. Company insiders own 3.60% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Envestnet Asset Management Inc. grew its position in shares of GW Pharmaceuticals PLC- by 4.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 2,014 shares of the biopharmaceutical company’s stock worth $347,000 after buying an additional 92 shares during the period. Steward Partners Investment Advisory LLC grew its position in GW Pharmaceuticals PLC- by 9.4% in the 3rd quarter. Steward Partners Investment Advisory LLC now owns 1,163 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 100 shares during the period. Close Asset Management Ltd grew its position in GW Pharmaceuticals PLC- by 13.5% in the 2nd quarter. Close Asset Management Ltd now owns 876 shares of the biopharmaceutical company’s stock valued at $151,000 after purchasing an additional 104 shares during the period. Aperio Group LLC grew its position in GW Pharmaceuticals PLC- by 4.0% in the 2nd quarter. Aperio Group LLC now owns 2,763 shares of the biopharmaceutical company’s stock valued at $476,000 after purchasing an additional 106 shares during the period. Finally, D.A. Davidson & CO. grew its position in GW Pharmaceuticals PLC- by 3.3% in the 2nd quarter. D.A. Davidson & CO. now owns 3,611 shares of the biopharmaceutical company’s stock valued at $623,000 after purchasing an additional 117 shares during the period. 83.39% of the stock is owned by institutional investors.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Read More: FAANG Stocks

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC- (GWPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.